Chronic Pain - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 335
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C6CB3F3B771EN
Leaflet:

Download PDF Leaflet

Chronic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chronic Pain - Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Chronic Pain
  • The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Pain
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Chronic Pain Overview
Therapeutics Development
Pipeline Products for Chronic Pain - Overview
Pipeline Products for Chronic Pain - Comparative Analysis
Chronic Pain - Therapeutics under Development by Companies
Chronic Pain - Therapeutics under Investigation by Universities/Institutes
Chronic Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chronic Pain - Products under Development by Companies
Chronic Pain - Products under Investigation by Universities/Institutes
Chronic Pain - Companies Involved in Therapeutics Development
AbbVie Inc
Acadia Pharmaceuticals Inc.
Adynxx, Inc.
Allergan Plc
Amorsa Therapeutics Inc.
arGEN-X BV
Asana BioSciences, LLC
AskAt Inc.
Astraea Therapeutics, LLC
Axsome Therapeutics, Inc.
BioDelivery Sciences International, Inc.
Biogen Inc
Bionomics Limited
Camurus AB
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
ChironWells GmbH
Collegium Pharmaceutical, Inc.
Crinetics Pharmaceuticals, Inc.
Cyclenium Pharma, Inc.
Cytogel Pharma, LLC
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dompe Farmaceutici S.p.A.
Echo Pharmaceuticals B.V.
Egalet Corporation
Eli Lilly and Company
Elite Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd.
Grunenthal GmbH
Heron Therapeutics, Inc.
INSYS Therapeutics, Inc.
Johnson & Johnson
Kareus Therapeutics, SA
KPI Therapeutics, Inc.
Kymab Limited
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Lpath, Inc.
MD Biosciences GmbH
Merck & Co., Inc.
Moberg Pharma AB
Mundipharma International Ltd
Nanomerics Ltd
Nektar Therapeutics
Neura Therapeutik, LLC
Orion Oyj
Pacira Pharmaceuticals, Inc.
Pain Therapeutics, Inc.
PeriphaGen, Inc.
Pfizer Inc.
Phosphagenics Limited
Prismic Pharmaceuticals, Inc.
Purdue Pharma LP
Relmada Therapeutics, Inc.
Ribomic Inc.
Sea4Us
Shulov Innovative Science Ltd.
Synactix Pharmaceuticals, Inc.
Syntrix Biosystems, Inc.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd.
Trevena, Inc.
Voyager Therapeutics, Inc.
Yooyoung Pharmaceutical Co., Ltd.
Zynerba Pharmaceuticals, Inc.
Chronic Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(celecoxib + tramadol hydrochloride) - Drug Profile
(hydrocodone bitartrate + palmidrol) - Drug Profile
(morphine sulfate + palmidrol) - Drug Profile
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
(oxycodone hydrochloride + palmidrol) - Drug Profile
(palmidrol + pregabalin) - Drug Profile
A-200 - Drug Profile
AGN-XX - Drug Profile
AGN-YY - Drug Profile
AMS-520 - Drug Profile
ASN-008 - Drug Profile
AVLX-144 - Drug Profile
AXS-06 - Drug Profile
AYX-1 - Drug Profile
AYX-2 - Drug Profile
BBI-11008 - Drug Profile
bupivacaine - Drug Profile
bupivacaine hydrochloride - Drug Profile
buprenorphine hydrochloride - Drug Profile
buprenorphine hydrochloride depot - Drug Profile
buprenorphine hydrochloride ER - Drug Profile
buprenorphine hydrochloride long acting - Drug Profile
cebranopadol - Drug Profile
cetirizine hydrochloride + cromolyn sodium - Drug Profile
cetuximab - Drug Profile
CNTX-0290 - Drug Profile
CNV-3000164 - Drug Profile
CNV-3000223 - Drug Profile
CR-4056 - Drug Profile
CR-701 - Drug Profile
CRB-0089 - Drug Profile
Cyt-1010 - Drug Profile
dexmedetomidine hydrochloride - Drug Profile
DF-2593A - Drug Profile
difelikefalin - Drug Profile
dronabinol - Drug Profile
DS-1971 - Drug Profile
DWJ-208 - Drug Profile
ECP-1014 - Drug Profile
Egalet-003 - Drug Profile
fluticasone propionate - Drug Profile
FY-101C - Drug Profile
FY-103B - Drug Profile
GBR-900 - Drug Profile
Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile
grapiprant - Drug Profile
HPI-201 - Drug Profile
HS-731 - Drug Profile
hydrocodone bitartrate ER - Drug Profile
hydrocodone bitartrate ER - Drug Profile
hydrocodone bitartrate ER - Drug Profile
hydromorphone hydrochloride - Drug Profile
Kindolor - Drug Profile
KY-1017 - Drug Profile
L-779976 - Drug Profile
lacosamide - Drug Profile
LEVI-04 - Drug Profile
levorphanol tartrate ER - Drug Profile
Lpathomab - Drug Profile
MD-354 - Drug Profile
Monoclonal Antibodies for Chronic Pain - Drug Profile
Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile
morphine sulfate ER - Drug Profile
MR-309 - Drug Profile
NET-END - Drug Profile
NKTR-181 - Drug Profile
NL-001 - Drug Profile
NL-002 - Drug Profile
NM-0127 - Drug Profile
Omnitram - Drug Profile
onabotulinumtoxin A - Drug Profile
OSX-300 - Drug Profile
OSX-300 Backups - Drug Profile
oxycodone hydrochloride ER - Drug Profile
oxycodone hydrochloride ER - Drug Profile
oxycodone hydrochloride ER - Drug Profile
oxymorphone hydrochloride - Drug Profile
oxymorphone hydrochloride ER - Drug Profile
PAC-CP - Drug Profile
palmidrol - Drug Profile
Peptide to Block Cav2.2 for CNS Disorders - Drug Profile
Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
PN-6047 - Drug Profile
PRC-062 - Drug Profile
Prostatic Acid Phosphatase - Drug Profile
PspTx-3 - Drug Profile
raxatrigine hydrochloride - Drug Profile
RBM-005 - Drug Profile
REL-1017 - Drug Profile
SAFit2 - Drug Profile
Small Molecule for Chronic Pain - Drug Profile
Small Molecule for Chronic Pain - Drug Profile
Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile
Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile
Small Molecules for Chronic Wound Pain - Drug Profile
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile
Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile
Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile
Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile
Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile
Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile
Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile
Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile
SYN-003 - Drug Profile
Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile
tanezumab - Drug Profile
tapentadol hydrochloride IR - Drug Profile
TRV-734 - Drug Profile
U-2902 - Drug Profile
UMB-425 - Drug Profile
Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile
VM-902A - Drug Profile
VYNAV-01 - Drug Profile
XT-101 - Drug Profile
YYC-301 - Drug Profile
ZEP-3 - Drug Profile
ZYN-001 - Drug Profile
Chronic Pain - Dormant Projects
Chronic Pain - Discontinued Products
Chronic Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 326

LIST OF TABLES

Number of Products under Development for Chronic Pain, H2 2016
Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2016
Chronic Pain - Pipeline by AbbVie Inc, H2 2016
Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
Chronic Pain - Pipeline by Adynxx, Inc., H2 2016
Chronic Pain - Pipeline by Allergan Plc, H2 2016
Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016
Chronic Pain - Pipeline by arGEN-X BV, H2 2016
Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016
Chronic Pain - Pipeline by AskAt Inc., H2 2016
Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016
Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016
Chronic Pain - Pipeline by Biogen Inc, H2 2016
Chronic Pain - Pipeline by Bionomics Limited, H2 2016
Chronic Pain - Pipeline by Camurus AB, H2 2016
Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
Chronic Pain - Pipeline by ChironWells GmbH, H2 2016
Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016
Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016
Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016
Chronic Pain - Pipeline by Egalet Corporation, H2 2016
Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016
Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016
Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016
Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by Johnson & Johnson, H2 2016
Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016
Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by Kymab Limited, H2 2016
Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016
Chronic Pain - Pipeline by Lpath, Inc., H2 2016
Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016
Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016
Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016
Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016
Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016
Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016
Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016
Chronic Pain - Pipeline by Orion Oyj, H2 2016
Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016
Chronic Pain - Pipeline by Pfizer Inc., H2 2016
Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016
Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016
Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by Ribomic Inc., H2 2016
Chronic Pain - Pipeline by Sea4Us, H2 2016
Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016
Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016
Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016
Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016
Chronic Pain - Pipeline by Trevena, Inc., H2 2016
Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016
Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Chronic Pain - Dormant Projects, H2 2016
Chronic Pain - Dormant Projects (Contd..1), H2 2016
Chronic Pain - Dormant Projects (Contd..2), H2 2016
Chronic Pain - Dormant Projects (Contd..3), H2 2016
Chronic Pain - Dormant Projects (Contd..4), H2 2016
Chronic Pain - Dormant Projects (Contd..5), H2 2016
Chronic Pain - Dormant Projects (Contd..6), H2 2016
Chronic Pain - Dormant Projects (Contd..7), H2 2016
Chronic Pain - Dormant Projects (Contd..8), H2 2016
Chronic Pain - Discontinued Products, H2 2016
Chronic Pain - Discontinued Products (Contd..1), H2 2016
Chronic Pain - Discontinued Products (Contd..2), H2 2016 325

LIST OF FIGURES

Number of Products under Development for Chronic Pain, H2 2016
Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Osteoarthritis Pain - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 212 pages

Ask Your Question

Chronic Pain - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: